Nextcure
$10.72
6
+$0.19+1.8% Thursday 20:00
Statistics
Day High
10.72
Day Low
10.31
52W High
15.74
52W Low
2.69
Volume
10,781
Avg. Volume
34,275
Mkt Cap
28.73M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30AprExpected
Expected EPS
-1.83
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-111.31MNet Income
Analyst Ratings
$18.00Average Price Target
The highest estimate is 18.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NXTC. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Novartis
NVS
Mkt Cap237.61B
Gilead Sciences
GILD
Mkt Cap148.78B
Merck
MRK
Mkt Cap214.76B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
AMGEN
AMGN
Mkt Cap160.66B
About
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Show more...
CEO
Mr. Michael S. Richman MSBA
Employees
43
Country
US
ISIN
US65343E2072
Listings
0 Comments
Share your thoughts
FAQ
What is Nextcure stock price today?▼
The current price of NXTC is $10.72 USD — it has increased by +1.8% in the past 24 hours. Watch Nextcure stock price performance more closely on the chart.
What is Nextcure stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nextcure stocks are traded under the ticker NXTC.
Is Nextcure stock price growing?▼
NXTC stock has risen by +7.09% compared to the previous week, the month change is a -11.04% fall, over the last year Nextcure has showed a +125.02% increase.
What is Nextcure market cap?▼
Today Nextcure has the market capitalization of 28.73M
When is the next Nextcure earnings date?▼
Nextcure is going to release the next earnings report on April 30, 2026.
What were Nextcure earnings last quarter?▼
NXTC earnings for the last quarter are -0.46 USD per share, whereas the estimation was -2.29 USD resulting in a +79.91% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nextcure revenue for the last year?▼
Nextcure revenue for the last year amounts to 0 USD.
What is Nextcure net income for the last year?▼
NXTC net income for the last year is -111.31M USD.
How many employees does Nextcure have?▼
As of April 03, 2026, the company has 43 employees.
In which sector is Nextcure located?▼
Nextcure operates in the Health Care sector.
When did Nextcure complete a stock split?▼
The last stock split for Nextcure was on July 14, 2025 with a ratio of 1:12.
Where is Nextcure headquartered?▼
Nextcure is headquartered in Beltsville, US.